Sol-Gel将向PellePharm支付470万美元的预付款,以及高达600万美元的开发和NDA验收里程碑,以及高达6400万美元的商业里程碑和分成。
Patidegib被Sol-Gel指定为SGT-610,用于治疗Go...查看全文
$Sol-gel(SLGL)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001178913-21-002510 Act: 34 Size: 2 MB 网页链接
$Sol-gel(SLGL)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001178913-21-002512 Act: 34 Size: 4 MB 网页链接
$Sol-gel(SLGL)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001178913-21-002387 Act: 34 Size: 38 KB 网页链接
$Sol-gel(SLGL)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001178913-21-002251 Act: 34 Size: 14 KB 网页链接
$Sol-gel(SLGL)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001178913-21-002159 Act: 34 Size: 4 MB 网页链接
$Sol-gel(SLGL)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001178913-21-002157 Act: 34 Size: 66 KB 网页链接
$Sol-gel(SLGL)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001178913-21-002120 Act: 34 Size: 7 MB 网页链接
$Sol-gel(SLGL)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001178913-21-001969 Act: 34 Size: 241 KB 网页链接
$Sol-gel(SLGL)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001178913-21-001959 Act: 34 Size: 7 MB 网页链接
$Sol-gel(SLGL)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001178913-21-001875 Act: 34 Size: 133 KB 网页链接